Can Men Get the HPV Vaccine? What the Evidence Actually Shows

Yes, men can get the HPV vaccine, and in the United States the Food and Drug Administration has licensed it for males since 2009. Gardasil 9 is approved for everyone ages 9 through 45, so an adult man of any age in that window can legally and safely receive it. The catch is not permission but timing: the vaccine prevents new infections rather than clearing existing ones, so it delivers the most benefit before sexual exposure begins. The CDC's Advisory Committee on Immunization Practices routinely recommends it for boys at ages 11 to 12, with catch-up vaccination through age 26 for anyone not previously vaccinated.

How the vaccine blocks infection before cancer can start

The HPV vaccine is not a treatment and cannot remove a virus you already carry. It works entirely by prevention, which explains nearly every guideline you will read about it.

Gardasil 9 is a recombinant vaccine built from the L1 major capsid protein of nine HPV types. Manufacturers assemble these proteins into virus-like particles, empty shells that look identical to the real virus to the immune system but contain no viral DNA. Your B cells respond by producing neutralizing antibodies against the L1 surface, so when the actual virus arrives at the basement membrane of skin or mucosal tissue, antibodies bind it before it can enter basal cells. In plain terms: the vaccine trains your immune system to recognize the virus's outer coat, and a coated virus cannot break into a cell.

That mechanism has a critical timing consequence. HPV must infect basal epithelial cells through a microabrasion, and once it establishes itself, it hijacks the cell's replication machinery and can persist for years. Antibodies from the vaccine circulate in the bloodstream and at mucosal surfaces; they block new exposure events, not established infection. This is why every efficacy trial measured outcomes in people who were HPV-naive at enrollment, and why the vaccine's protection against a type you already have is close to zero.

The vaccine is also prophylactic in a second sense: it is not therapeutic. A 2019 meta-analysis of therapeutic HPV vaccine trials found no licensed product reliably clears existing infection or cervical lesions. So the question "can men get it" has a practical corollary: it works best when given before exposure, not after.

What the numbers show for males

The evidence base for males is smaller than for females but consistent. The landmark quadrivalent vaccine trial in men, published by Giuliano and colleagues in 2011, enrolled 4,065 men aged 16 to 26 and found the vaccine reduced external genital lesions by about 90 percent in the per-protocol population. That number applies to men who were HPV-naive at enrollment; the intention-to-treat figure was lower because some men already carried the types at baseline.

For context, HPV is the most common sexually transmitted infection in the United States. The CDC estimates about 42 million Americans currently carry genital HPV, with roughly 13 million new infections each year. Prevalence in men is high: studies of unvaccinated men report detectable genital HPV DNA in roughly 50 percent of sexually active adults at any given time, and most infections are asymptomatic and clear within one to two years.

The cancer burden in men is where the case for vaccination gets its teeth. HPV causes an estimated 70 percent of oropharyngeal cancers in the United States, and oropharyngeal cancer incidence in men has been rising while cervical cancer rates have fallen. The CDC attributes about 15,000 HPV-associated cancers per year to men, compared with roughly 21,000 to women. The male share is dominated by throat cancer (about 12,000 cases) and anal cancer (about 3,000), with penile cancer adding a few hundred. There is no routine screening for any of these in men, which is a key argument for prevention.

The asymmetry matters: women have a screening net that catches precancerous cervical lesions early. Men have no equivalent net for throat or penile cancer, so the vaccine is the only primary prevention tool for the cancers that hit them hardest.

Age, dose, and timing variations

The schedule is not one-size-fits-all, and the threshold that decides the number of doses is age 15.

Anyone who starts the series before their 15th birthday needs two doses, with the second given 6 to 12 months after the first. Anyone who starts at 15 or older, or who is immunocompromised at any age, needs three doses at 0, 1 to 2, and 6 months. The reason is immunological: younger adolescents mount a stronger antibody response per dose, so two shots suffice. Adults need the third dose to reach comparable titers.

For men, the catch-up window runs through age 26 under routine ACIP recommendations. Beyond 26, the guidance shifts from routine to shared clinical decision-making for adults aged 27 through 45. That phrase is not a prohibition; it means a clinician should weigh individual risk factors, such as number of sexual partners, immune status, and history of HPV-related lesions, before recommending it. The vaccine is approved and available through age 45 regardless.

Efficacy drops sharply when the vaccine is given after exposure. In the Giuliano trial, the per-protocol efficacy against persistent infection with the four vaccine types was about 86 percent, but the intention-to-treat efficacy against any lesion was lower precisely because baseline HPV positivity diluted the effect. A man who is already sexually active and HPV-positive for one type still benefits from protection against the other eight types in Gardasil 9, which is a commonly missed point.

The timeline from dose to protection

The immune response to the HPV vaccine is slower than most people assume, and the series takes months to complete.

The two-dose schedule for adolescents compresses this: dose two at month 6 to 12, with protection considered complete about two weeks after the final dose. A man who starts the series today is not protected against a new exposure next week; the practical window to full protection is roughly seven months on the three-dose schedule.

Misconceptions and the edge cases that matter

The most persistent misconception is that the vaccine is only for girls. That belief dates to the 2006 approval for females; male approval followed in 2009, and the ACIP routine recommendation for boys came in 2011. By 2026, the gender gap in uptake has narrowed but not closed: CDC data from recent years show male adolescent completion rates at roughly 60 percent versus about 65 percent for females, leaving a meaningful prevention gap.

A second misconception is that vaccination after sexual debut is pointless. It is not, but the benefit is smaller and depends on which types you already carry. If you are HPV-negative for the nine vaccine types, the vaccine works about as well as it would have before debut. If you carry one type, you still gain protection against the other eight. The only truly wasted scenario is vaccination after you have already been infected with all nine types, which is rare.

The counterintuitive edge case is the immunocompromised man. Men with HIV, or those on immunosuppressive therapy after transplant, are at substantially higher risk of persistent HPV infection and HPV-related cancer, and they need the three-dose schedule regardless of age at initiation. Some guidelines extend catch-up vaccination for this group beyond 26, and the shared decision-making conversation at 27 to 45 leans strongly toward vaccination here. That nuance is often lost in the simplified "through 26" rule.

What to actually do if you are a man considering it

The practical steps are straightforward and mostly logistical, not medical.

• Check your age against the threshold: routine recommendation through 26, shared decision-making from 27 to 45, and the three-dose schedule if you start at 15 or older.
• Ask whether your insurance covers it; most US plans cover the full series under preventive care, and the Vaccines for Children program covers eligible people through age 18.
• Complete the series on schedule. A single dose provides partial protection but is not a completed series, and reports suggest one-dose regimens show promise in trials but are not yet the standard of care as of 2026.
• Do not wait for a "clean" HPV test before vaccinating; the vaccine protects against types you do not have, and there is no clinical requirement for baseline testing.
• If you are immunocompromised or over 26, raise it explicitly with your clinician rather than assuming you are ineligible.

Where the evidence is still thin and what it does not promise

The male evidence base rests on fewer trials than the female one, and the long-term cancer-reduction data are more mature for cervical cancer than for oropharyngeal cancer. The causal link between HPV and throat cancer is established, but quantifying how much male vaccination will reduce throat cancer incidence over decades is an extrapolation from infection and lesion endpoints, not a directly observed cancer reduction. That distinction is worth holding onto.

The vaccine also does not cover every cancer-causing HPV type. Gardasil 9 targets types 6, 11, 16, 18, 31, 33, 45, 52, and 58; types 16 and 18 account for about 70 percent of HPV-related cancers, so a residual risk remains even after full vaccination. It does not eliminate the need for any future screening that may emerge, and it does not treat existing infection or lesions. For men, the honest bottom line is that the vaccine is approved, recommended, and effective at preventing new infections and the cancers they cause, but it is a preventive tool with a timing window, not a cure or a universal shield.